8-K
filed October 20, 2023, 7:59 PM ET
CIK 0001100397
M&A
confidence high
sentiment neutral
materiality 0.65
Ayala Pharmaceuticals, Inc.: M&A transaction — Ayala Pharmaceuticals closes merger with Biosight, adds AML drug aspacytarabine
Ayala Pharmaceuticals, Inc.
- Merger completed Oct 18, 2023; ~5.9M Ayala shares issued to former Biosight holders at 1.82285 exchange ratio.
- Pipeline expands: adds aspacytarabine (BST-236) for AML; Phase 3 AL102 for desmoid tumors continues.
- Roy Golan appointed CFO, replacing interim CFO Igor Gitelman, effective at closing.
- Board changes: Dr. Samir Khleif resigned; new directors Yuval Cabilly, Pini Orbach, Bridget Martell appointed.
- Combined company continues on OTCQX under ticker ADXS.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
Bridget Martell was appointed as Director at Ayala Pharmaceuticals, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
Bridget Martell, M.D.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Samir Khleif resigned as Director at Ayala Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
immediately prior to the Effective Time, Dr. Samir Khleif resigned from the Board of the Registrant.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Roy Golan was appointed as Chief Financial Officer at Ayala Pharmaceuticals, Inc..
- Action
- appointed
- Role
- Chief Financial Officer
Exact text from the filing
Effective as of the Effective Time, Roy Golan, CPA, LLM, will become the Registrant’s Chief Financial Officer.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Yuval Cabilly was appointed as Director at Ayala Pharmaceuticals, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
Yuval Cabilly, Ph.D .
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Igor Gitelman departed as Interim Chief Financial Officer at Ayala Pharmaceuticals, Inc..
- Action
- ceased to serve
- Role
- Interim Chief Financial Officer
Exact text from the filing
Igor Gitelman will cease to serve as the Company’s Interim Chief Financial Officer at that time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Pini Orbach was appointed as Director at Ayala Pharmaceuticals, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
Pini Orbach, Ph.D .
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Ayala Pharmaceuticals, Inc. completed an acquisition involving Biosight Ltd. (closed 2023-10-18).
- Action
- acquisition
- Counterparty
- Biosight Ltd.
- Closing
- 2023-10-18
Exact text from the filing
On October 18, 2023 (the “Closing Date”), pursuant to the Merger Agreement, Merger Sub consummated the merger with and into Biosight, with Biosight continuing as the surviving company and a wholly-owned subsidiary of the Registrant (the “Merger”).
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.